While RYR has demonstrated lipid-modulating efficacy comparable to moderate-intensity statin therapy, there are several important factors that prevent it from being a replacement for statin medications. First, there is a much larger body of evidence supporting the effectiveness and relative safety of statin medications compared to RYR both in the short-term and long-term, and it is well established that statins can lower LDL cholesterol and reduce the risk of heart attacks, strokes, and mortality.[1][2] As prescription medications, the quality of statins is tightly regulated, and you can be highly confident that your medication contains the labeled amount of the active ingredient. As a supplement, RYR is not regulated for quality and batch-to-batch variability, and poor manufacturing practices can result in both inadequate or unknown amounts of the active compounds, and an increased likelihood of the supplement containing potentially harmful compounds. Additionally, in some countries (including Canada and the US), the sale of RYR supplements with anything more than trace amounts of monacolin K is prohibited, which would be expected to dramatically reduce its effectiveness.
References
- ^Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik MStatin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA.(2022-Aug-23)
- ^Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel MEfficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.QJM.(2011-Feb)